Nielsen H, Bonde J
Int J Immunopharmacol. 1986;8(6):589-92. doi: 10.1016/0192-0561(86)90030-5.
RU 41.740 (Biostim), a glycoprotein extract from Klebsiella pneumoniae, which is effective in heightening resistance to experimental infections in animals, was examined with regard to influence on human blood monocyte function in vitro after administration to patients with chronic bronchitis in a randomized, double-blind clinical trial. Twelve patients were given Biostim orally (seven patients received 8 mg daily and five patients received 2 mg daily) while eight patients received placebo. In the Biostim group monocyte phagocytosis increased from 1.4 yeast cells per monocyte before therapy to 3.1 yeast cells per monocyte after 1 month (P less than 0.05) with no further increase after 3 months. Monocyte candidacidal activity increased in the Biostim group from 51% before therapy to 69% after 1 month (P less than 0.05) with a decrease to 57% after 3 months. As expected, placebo had no significant effect on monocyte functions. There was no difference between the improvement in the high dose vs the low dose group. These results suggest that Biostim exerts part of its immunostimulatory property by stimulating blood monocyte antimicrobial function.
RU 41.740（生物刺激素）是一种从肺炎克雷伯菌中提取的糖蛋白提取物，对提高动物对实验性感染的抵抗力有效。在一项随机、双盲临床试验中，研究人员对慢性支气管炎患者给药后，其对人体血液单核细胞功能的体外影响进行了研究。12名患者口服生物刺激素（7名患者每天服用8毫克，5名患者每天服用2毫克），而8名患者服用安慰剂。在生物刺激素组中，单核细胞吞噬作用从治疗前每个单核细胞吞噬1.4个酵母细胞增加到1个月后每个单核细胞吞噬3.1个酵母细胞（P<0.05），3个月后没有进一步增加。生物刺激素组单核细胞杀念珠菌活性从治疗前的51%增加到1个月后的69%（P<0.05），3个月后降至57%。正如预期的那样，安慰剂对单核细胞功能没有显著影响。高剂量组和低剂量组的改善情况没有差异。这些结果表明，生物刺激素通过刺激血液单核细胞的抗菌功能发挥其部分免疫刺激特性。
